Kocsis 1995.

Methods	Design: NRCT Phases: acute (6–10 weeks), continuation (16–20 weeks), maintenance (104.4 weeks) Comparison groups: imipramine vs desipramine Funded by: no information
Participants	Number of participants randomized (NRCT: number of participants included): 73 Criteria for relapse/recurrence: no information; this outcome was not addressed. Age distribution in sample (mean): 36.0 (SD 10.0) years Sex distribution in sample (% women): 64.1 Diagnoses in sample: 37.0% dysthymia, 63.0% double depression Depression severity at continuation/maintenance baseline: unclear Age of onset: unclear Length current/last major episode in months: unclear
Interventions	Continuation treatment (16–20 weeks) Imipramine (participants = 23) Name (class and type): imipramine (TCA) Planned dosage of drug: 300 mg/day Dosage of drug: unclear Sertraline (participants = 50) Name (class and type): desipramine (TCA) Planned dosage of drug: 200 mg/day Dosage of drug (mean): 232 (SD 72) mg/day Notes: "Patients were allowed to remain in stable long‐term psychotherapy during the study but were not allowed to enter into new psychotherapy arrangements." (p. 214) No data provided about the percentage of participants receiving parallel psychotherapy. "Concomitant psychotropic medications were proscribed." (p. 214)
Outcomes	Dropout any Dropout due to adverse event
Notes	There were 3 different treatment arms in the acute treatment, but it was unclear how participants were allocated to the different treatment arms, e.g. if there were randomized. Additionally, the rationale of the acute treatment was unclear (e.g. some participants received medication on a double blind and some on an open basis).